前列腺特异性抗原最低值与达最低值时间预测根治性前列腺切除术后挽救性放疗患者的复发
本研究回顾性纳入15个欧洲中心1189例根治性前列腺切除术后生化复发并接受挽救性放疗(未联合雄激素剥夺治疗)的患者,按PSA最低值(<0.1 vs ≥0.1 ng/ml)和达最低值时间(<6 vs ≥6个月)分为四组。主要终点为无远处转移生存(DMFS),次要终点为无生化复发生存(BRFS)。结果显示PSA最低值深度与达最低值时间联合可改善预后分层。
要点
- PSA最低值<0.1 ng/ml且达最低值时间≥6个月者5年DMFS率达96%。
- PSA最低值≥0.1 ng/ml且达最低值时间<6个月者5年DMFS率仅63%。
- PSA最低值≥0.1 ng/ml和达最低值时间<6个月均为独立不良预后因素。
核心结论
- 挽救性放疗后PSA最低值深度与达最低值时间联合可改善生化复发患者的预后分层。
研究设计与样本
- 回顾性纳入15个欧洲中心1189例根治性前列腺切除术后接受挽救性放疗且未联合雄激素剥夺治疗的患者。
- 按PSA最低值(<0.1 vs ≥0.1 ng/ml)和达最低值时间(<6 vs ≥6个月)分为四组。
- 主要终点为无远处转移生存(DMFS),次要终点为无生化复发生存(BRFS)。
主要发现
- 中位临床随访4.4年(四分位距2.7-6.4年),5年BRFS率为62%(95%CI 59-65%),5年DMFS率为89%(95%CI 87-91%)。
- PSA最低值<0.1 ng/ml且达最低值时间≥6个月者(占56.3%)5年DMFS率为96%(95%CI 94-98%)。
- PSA最低值≥0.1 ng/ml且达最低值时间<6个月者(占14.7%)5年DMFS率为63%(95%CI 55-72%)。
- 多因素分析显示PSA最低值≥0.1 ng/ml为独立不良因素:BRFS的HR为10.1(95%CI 8.0-12.7),DMFS的HR为7.1(95%CI 4.5-11.2)。
- 多因素分析显示达最低值时间<6个月为独立不良因素:BRFS的HR为3.0(95%CI 2.3-3.8),DMFS的HR为1.8(95%CI 1.1-2.7)。
临床怎么用
- 可利用挽救性放疗后PSA最低值深度和达最低值时间联合对生化复发患者进行预后分层。
- 预后分层可能有助于在监测、主动治疗和治疗升级之间做出个体化决策。
局限性
- 本研究为回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Salvage radiotherapy (SRT) is often curative in men with biochemical recurrence (BCR) after radical prostatectomy (RP); however, a subset experiences progression. While the depth of prostate-specific antigen (PSA) nadir after SRT is a known prognostic factor, its combined role with time to nadir (TTN) in the salvage setting, in absence of androgen deprivation therapy (ADT), has not been evaluated systematically and the present study aims to evaluate it. METHODS: We retrospectively included RP patients treated with SRT across 15 European centers. No prior or concomitant ADT was allowed. Patients were stratified into four groups by PSA nadir (<0.1 vs ≥0.1 ng/ml) and TTN (<6 vs ≥6 mo). The primary endpoint was distant metastasis-free survival (DMFS). The secondary endpoint was BCR-free survival (BRFS). KEY FINDINGS AND LIMITATIONS: A total of 1189 patients were included in the study, with a median clinical follow-up of 4.4 (interquartile range, 2.7-6.4) yr, and 5-yr BRFS and DMFS probabilities of 62% (95% confidence interval [CI], 59-65%) and 89% (95% CI, 87-91%), respectively. Patients with favorable kinetics (nadir <0.1 ng/ml, TTN ≥6 mo; 56.3% of cohort) achieved a 5-yr DMFS rate of 96% (95% CI, 94-98%), while high-risk patients (nadir ≥0.1 ng/ml, TTN <6 mo; 14.7%) had poor outcomes (5-yr DMFS rate 63%; 95% CI, 55-72%). A multivariable analysis confirmed a nadir of ≥0.1 ng/ml (hazard ratio [HR] 10.1; 95% CI, 8.0-12.7 for BRFS, and HR 7.1; 95% CI, 4.5-11.2 for DMFS) and TTN <6 mo (HR 3.0; 95% CI, 2.3-3.8, and HR 1.8; 95% CI, 1.1-2.7, respectively) as independent adverse factors. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study showed that the combination of PSA nadir depth and TTN after SRT allows an improvement in prognostic stratification of SRT patients with BCR after RP. These findings might improve patient-tailored decisions between surveillance, active treatment, and treatment escalation.
引用
- Mastroleo F, Villa R, Zaffaroni M, et al. Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation Therapy. Eur Urol Oncol. 2025. PMID: 41402161. doi:10.1016/j.euo.2025.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。